6-K 1 tm2413095d1_6k.htm FORM 6-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

  

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of April 2024

 

Commission File Number:  001-39458

 

Medicenna Therapeutics Corp.

 

(Translation of registrant’s name into English)

 

2 Bloor St. W. 7th Floor

Toronto, Ontario M4W 3E2

Canada 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

  x Form 20-F ¨ Form 40-F  

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  Medicenna Therapeutics Corp.
  (Registrant)
     
Date: April 30, 2024 By:   /s/ Fahar Merchant
    Name: Fahar Merchant, PhD
    Title: Chief Executive Officer

 

 

 

 

Form 6-K Exhibit Index

 

Exhibit
Number
  Document Description
     
99.1   Press Release of the Registrant dated April 30, 2024
99.2   Material Change Report of the Registrant dated April 30, 2024
99.3   Pre-Funded Warrant Certificate